ArticleViruses2021
Emerging Phage Resistance in
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage-Driven Resistance.Microbial biotechnology · 2026Article
- Article
- Isolation and Genomic Characterization of LyticLife (Basel, Switzerland) · 2026Article
- Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Immuno-phage synergy driven by fitness costs: turning bacterial phage resistance into therapeutic gain through evolutionary traps.Frontiers in immunology · 2026Review
- A case report of bacteriophage therapy for the treatment of lung infection due to carbapenem-resistant Pseudomonas aeruginosa.Scientific reports · 2025Article
- Isolation, Characterization, and Genomic Analysis of Bacteriophages AgainstMicroorganisms · 2025Article
- Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.Clinical microbiology reviews · 2024Review
- Diversification ofMicroorganisms · 2024Article
- Article
- The current state of phage therapy in livestock and companion animals.Journal of animal science and technology · 2024Review
- The trade-off ofFrontiers in microbiology · 2024Article
- Combination of genetically diverse Pseudomonas phages enhances the cocktail efficiency against bacteria.Scientific reports · 2023Article
- The impact of agarose immobilization on the activity of lytic Pseudomonas aeruginosa phages combined with chemicals.Applied microbiology and biotechnology · 2023Article
- Disarm The Bacteria: What Temperate Phages Can Do.Current issues in molecular biology · 2023Review
- Resistance against two lytic phage variants attenuates virulence and antibiotic resistance inFrontiers in cellular and infection microbiology · 2023Article
- Relationship between Biofilm-Formation, Phenotypic Virulence Factors and Antibiotic Resistance in Environmental Pseudomonas aeruginosaPathogens (Basel, Switzerland) · 2022Article
- Increased Innate Immune Susceptibility in Hyperpigmented Bacteriophage-Resistant Mutants of Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2022Article
- Biological foundations of successful bacteriophage therapy.EMBO molecular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial surface structures of a proteinic nature and glycoconjugates contribute to biofilm formation and provide shields to host defense mechanisms (e.g., the complement system and phagocytosis). A loss or alteration of these molecules, leading to phage resistance, could result in fewer virulent bacteria. In this study, we evaluate the biology and phenotype changes in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.